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Synthesis of AG10 analogs and optimization of the structure of TTR Ligands for Half-
life Enhancement (TLHE) for peptides 
 
 
Abstract 
 
by 
Raghavendra Jampala 
 
UNIVERSITY OF THE PACIFIC 
2017 
 
 
 The misassembly of soluble proteins into toxic aggregates, including amyloid fibrils, 
underlies a large number of human degenerative diseases. Like cardiac amyloidosis, which is 
most commonly, caused by aggregation of Immunoglobulin (Ig) light chains or transthyretin 
(TTR) in the cardiac muscle, represent an important and often underdiagnosed cause of heart 
failure. TTR-mediated amyloid cardiomyopathies are chronic and progressive conditions that lead 
to arrhythmias, biventricular heart failure, and death. As no Food and Drug Administration-
approved drugs are currently available for treatment of these diseases, the development of 
therapeutic agents that prevent TTR-mediated cardiotoxicity is desired. AG10 is a potent and 
selective kinetic stabilizer of TTR. AG10 prevents dissociation of TTR in serum samples 
obtained from patients with amyloid cardiomyopathy. The oral bioavailability and selectivity of 
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AG10, makes it a very promising candidate to treat TTR amyloid cardiomyopathy. Understanding 
the reason behind the potency of AG10 would be beneficial for designing stabilizers for other 
amyloid diseases. This would be possible by designing and synthesizing structural analogues of 
AG10.  Here we report the synthesis, characterization and analysis of AG10 analogs and compare 
the in vitro activities of the synthesized analogs.  
The tremendous therapeutic potential of peptides has not been fulfilled and potential 
peptide therapies that have failed far outnumber the successes so far. A major challenge impeding 
the more widespread use of peptides as therapeutics is their poor pharmacokinetic profile, due to 
short in vivo half-life resulting from inactivation by serum proteases and rapid elimination by 
kidneys. Extending the in vivo half-life of peptides is clearly desirable in order for their 
therapeutic potential to be realized, without the need for high doses and/or frequent 
administration. Covalent conjugation of peptides to macromolecules (e.g. polyethylene glycol or 
serum proteins such albumin) has been the mainstay approach for enhancing the in vivo half-life 
of peptides. However, the steric hindrance and immunogenicity of these large macromolecules 
often compromises the in vivo efficacy of the peptides. Recently, our laboratory established the 
first successful reversible method of extending the half-life of peptides using serum protein 
Transthyretin (TTR). The approach involved the use of a TTR Ligand for Half-life Extension 
((TLHE-1) which binds to TTR with high specificity and affinity. We have shown that our 
technology extends the half-life of multiple peptides without seriously affecting their activity. 
Our main objective here is to modify the structure of the TLHE1 using linkers with different 
length and composition to optimize its affinity and selectivity for TTR in human serum. 
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Chapter 1.General Introduction 
1.1 Transthyretin 
Transthyretin (TTR) is a 55kDa homo-tetrameric protein present in both plasma and 
cerebrospinal fluid. TTR is synthesized by the liver and secreted into the blood, where it acts as a 
backup carrier for thyroxine (T4) and primary carrier of holo retinol-binding protein (RBP). The 
crystalline structure of transthyretin is showed in (Figure.1) [1, 2, 3]. TTR invokes great scientific and 
medical interest as it is one of more than 30 proteins whose aggregation could cause disease by a 
gaining toxic function mechanism leading to amyloid fibril formation, in nervous system, soft tissue, 
and solid organs [3]. TTR aggregation, dissociation, and misfolding are known to be primarily 
responsible for several amyloid-related diseases like familial amyloid polyneuropathy (FAP), familial 
amyloid cardiomyopathy (FAC) and senile systemic amyloidosis (SSA).  
 
 
 
Figure.1: Crystal structure image of Transtyretin
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TTR in plasma is primarily synthesized in the liver, while TTR in the brain is synthesized 
by choroid plexus.  TTR is also synthesized at lower amounts in several other tissues such as 
retinal pigment epithelium of the eye, islets of Langerhans of the pancreas, intestine and 
meninges [4].  TTR present in blood is produced and secreted by the hepatocytes in the liver. 
Normal TTR concentrations in healthy adults range between 0.2 – 0.4 mg/mL (3.5 – 7 µM) [5]. 
When the liver is participating in acute phase response to injury, malnutrition, or chronic 
inflammation there is a significant decrease in plasma or blood TTR levels. Hence, TTR levels 
are used as a marker for nutritional and inflammatory status in the clinic especially in settings 
where it is difficult to obtain a more detailed and comprehensive nutritional assessment such as 
evaluation of albumin, α1-acid glycoprotein, and C-reactive protein [6].  
1.2 Structure of TTR 
Human TTR is composed of four identical 127 amino acid residue subunits (~14 kDa) 
that form an extensive β-sheet structure [7]. The four identical subunits (or monomers) of TTR 
assemble to form an internal channel at the weaker dimer–dimer interface where two T4 
molecules could bind on the resulting tetramer [4, 7]. Recent studies have revealed that due to the 
presence of two other T4 transport proteins in blood these T4 binding sites remain largely 
unoccupied in humans (<1 % T4 bound) and among those occupied, only one site is filled as there 
is negative cooperativity in the binding of the second T4 [8, 9]. In addition to thyroid hormones 
(T4) and its metabolites, several other pharmacologic agents and natural products, such as plant 
flavonoids, nonsteroidal analgesic drugs, and inotropic bipyridines, are strong competitors for T4 
binding to TTR and have binding affinities greater than T4 [4, 10]. 
The structure of human wild-type TTR (WT-TTR) was one of the first proteins to be 
determined by X-ray crystallography [2]. Currently (as of June 2017), there are about 267 
reported TTR crystal structures and their variants listed in the Protein Data Bank (PDB, 
www.rcsb.org) representing five species of protein (human, rat, mouse, chicken, and fish). 
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Studies have shown that the amino acid sequence of human WT- TTR is about 85 % identical to 
that from various other species [11].  
1.3 Function and clinical importance of TTR 
The most important role of TTR is the transport of T4 and retinol. However, recent 
studies have indicated that TTR may also play an important physiological role in proteolysis and 
transport of other miscellaneous ligands [12]. TTR is not the primary transporter of T4 (less than 
1 % bound), due to the presence of two other T4 transport proteins in blood, thyroxine-binding 
globulin (TBG) and albumin, the T4 binding sites remain largely unoccupied in humans [13, 14]. 
However, in CSF, TTR is a major transporter of T4 in both humans and rats. Interestingly, unlike 
in human plasma, TTR is the major transporter of T4 in rats. As there is negative cooperativity 
between the two T4 binding pockets, each TTR tetramer carries no more than one T4 molecule at 
a time [15].  Retinol or vitamin A circulates in blood, bound to retinol binding protein (holo-RBP) 
which is found in complex with TTR. Evolution has proposed this association to facilitate RBP 
release from its site of synthesis in the endoplasmic reticulum and to prevent renal filtration of 
RBP [16, 17]. The presence of retinol bound to RBP is essential for the formation of a stable 
complex with TTR [18]. Structural studies revealed that the RBP binding site on TTR is 
orthogonal to TTR T4-binding pockets (Figure.1.1). In plasma, RBP binds to TTR in 1:1 molar 
ratio due to limited concentration of RBP available. Recently, TTR has shown to have protective 
effect against amyloid beta (Aβ) deposition in Alzheimer’s disease (AD). Studies have shown 
that TTR could bind and cleave soluble Aβ and prevents the Aβ amyloid fibril formation in vitro 
[19]. TTR cleaves Aβ in multiple positions generating shorter Aβ peptides displaying lower 
amyloidogenic potential. Also, TTR was able to degrade aggregated forms of Aβ and may 
contribute to maintenance of normal Aβ levels in the brain.  
Kinetic stabilizers of the native tetrameric structure of TTR by interallelic trans 
suppression in compound heterozygote patients, that carry both the destabilizing V30M as well as 
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a second, disease suppressing mutation (T119M) [20], or by a small molecule which occupies the 
T4-binding sites, raises a dissociative transition state energy and prevents amyloidosis (Figure 
1.2). Recently, clinical trial on tafamidis a TTR kinetic stabilizer, indicates that it slows the 
progression of early stage neuropathy in FAP patients [21]. Currently, they are no FDA-approved 
drugs for the treatment or prevention of FAC or SSA. As a result, therapy for most patients is 
confined to symptomatic reliefs. The treatment of choice to remove the mutated protein is by 
replacing the liver for hereditary TTR amyloidosis. Combined liver and heart transplantation is 
performed as a palliative measure for a subset of FAC patients [22]. The risk and cost of organ 
transplantation is substantial and transplant patient requires lifelong use of immune-suppressive 
drugs leading to morbidity. Due to these circumstances; there is an urgent need for a 
pharmacologic treatment of TTR cardiomyopathy.  
 We used high-throughput screening (HTS) for TTR ligands, which enabled the 
identification of a variety of potent and structurally very different TTR kinetic stabilizers. Our lab 
used the previous compounds as a starting point for structure-activity relationship studies and 
synthesized a series of analogs, one of which the best hits from HTS named AG10 [3] is a highly 
effective and selective stabilizer of TTR. Understanding the reason behind the potency of AG10 
would be beneficial for designing stabilizers for other amyloid diseases. This would be possible 
by designing and synthesizing structural analogues of AG10. Here we report the synthesis of 
AG10 analogs (Figure.2) and the evaluation of their in vitro activity in stabilizing TTR in 
comparison to tafamidis and AG10. 
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Figure.1.1: TTR bound to T4 and holo-Retinol-binding protein (holo-RBP). 
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Figure.1.2: The TTR amyloidogenesis cascade and a table summarizing TTR-mediated amyloidoses. TTR 
amyloidoses require rate-limiting tetramer dissociation to dimers, followed by dissociation into monomers 
before partial unfolding of monomers yields the aggregation-prone amyloidogenic intermediate. The 
amyloidogenic intermediate can misassemble to form a variety of toxic aggregates, including amyloid 
fibrils. Disease-associated destabilizing mutations can kinetically or thermodynamically destabilize TTR. 
Kinetic stabilization can be achieved through trans-allelic suppression with the kinetically stabilized 
T119M-TTR, binding to T4 or other small molecules (Lower Left). 
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Figure.1.3: Crystal structures of TTR ligand complexes. (A) Quaternary structure of 1 bound to WT-
TTR shown as a ribbon representation with monomers colored individually. (B) 1 in complex with WT-
TTR (3P3T). (C) AG10 in complex with V122I-TTR showing the introduced carboxylate making 
electrostatic salt bridge interactions with Lys15 and Lys15'. Close-up views of one of the two identical T4-
binding sites in a ribbon depicted tetramer colored by chain. A “Connolly” molecular surface was applied 
to residues within 10 Å of ligand in the T4-binding pocket hydrophobic (grey), polar (purple). The 
innermost halogen binding pockets (HBPs) 3 and 3′ are composed of the methyl and methylene groups of 
S117/117′, T119/119′, and L110/110′. HBPs 2 and 2′ are made up by the side chains of L110/110′, 
A109/109′, K15/15′, and L17/17′. The outermost HBPs 1 and 1′ are lined by the methyl and methylene 
groups of K15/15′, A108/108′, and T106/106′. Hydrogen bonds shown in light blue dashed lines, with the 
atomic distances labeled in Å. 
20 
 
Chapter 2. Synthesis of AG10 Analogs 
 
2.1 Methods and Materials 
Pre-albumin from human plasma (human TTR) was purchased from Sigma, probe was 
synthesized in lab. All other starting materials for the synthesis of AG10 analogs were purchased from 
Alfa Aesar and Accela. The solvents used were ACS grade purchased from Fisher Scientific, and reagents 
were purchased from Aldrich and Acros, and used without further purifications. Reactions were 
monitored using thin-layer chromatography (TLC) carried out on 0.2mm POLYGRAM® SIL silica gel 
plates with fluorescent indicator UV254 using UV light as a visualizer. For purification normal phase 
flash column chromatography was carried out using Davisil® silica gel (100-200 mesh, Fisher Scientific), 
High-resolution mass spectra (HRMS) were determined by JEOL AccuTOF DART using helium as an 
ionization gas and HPLC analysis was performed on a Waters™ Alliance 2790 system attached to 
Waters™ 2990 PDA detector operating between the UV ranges of 200 – 400 nm. A empower 2.0 data 
acquisition system was used for quantification purposes. A Waters™ XBridge C18 column with L1 
packing (4.6 X 150 mm, 5μm) was used at ambient temperature.  The UV absorbance was recorded at 
280 nm and 254 nm. 
21 
 
 
 
Figure.2: Structure of AG10, AG10 Analog 1 & AG10 Analog 2 showing difference in the position of 
fluorine. 
 
2.2 Chemical Synthesis of AG10 
 The chemical synthesis of AG10 is very similar to what was reported earlier for AG10 
[3]. The only difference is using different fluoro-aromatic ring as starting materials. 
2.3 Chemical Synthesis of AG10 Analog 1 
 
 
Figure.2.1: Synthesis of AG10 Analog 1. A) Methyl-2-fluoro-5-hydroxybenzoate, 4-(3-bromopropyl)-3,5-
dimethyl-1H-pyrazole, K2CO3, DMF, room temperature, 18-20 hrs; B) NaOH, water, MeOH, 50̊ C reflux, 
14 hrs. 
 
AG10 Analogue 2AG10 Analog 1AG10
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Methyl 5-(3-bromopropoxy)-2-fluoro-benzoate (2): the synthesis scheme of AG10 Analog 1 is 
depicted in (Fig. 2.1). To a solution of methyl 2-fluoro-5-hydroxybenzoate 1 (50 mg, 0.59 mmol, 
1 equiv) and 4-(3-bromopropyl)-3,5-di-methyl-1H-pyrazole (87 mg) in DMF (2 mL) was added 
K2CO3 (101 mg, 1.42 mmol, 2.5 equiv). The reaction mixture was stirred at room temperature 
(r.t.) for 16 hrs. The mixture was diluted with EtOAc (1.5 L), washed with brine (3x0.5 L) and 
dried with Na2SO4. The solution was filtered and concentrated. The residue was purified by flash 
column chromatography (silica gel, 1-10 % EtOAc/hexanes) to afford compound 2 (77 mg, 82 % 
yield). 
5-[23]-2-fluoro-benzoic acid (AG10 analog 1);  to a suspension of 2 (77 mg, 0.33 mmol, 1 
equiv) in a mixture of MeOH (1.5 mL) and water (500 µL), NaOH.H2O (21 mg, 0.50 mmol, 2 
equiv) was added. The reaction mixture was stirred at 50̊C reflux for 14 hrs. The mixture was 
extracted with EtOAc (3 x 30 mL) and the combined organic extracts were dried over anhydrous 
sodium sulfate and concentrated in vacuum. The crude product was subjected to flash column 
chromatography (silica gel, 10-50 % MeOH/CH2Cl2) to give of AG10 analog 1 (40 mg, 71% 
yield) as a white solid (>98 % purity by HPLC). 
23 
 
 
Figure.2.2. MS Data showing AG10 Analog 1 (M.WT: 292). 
  
Figure 2.3: HPLC trace of AG10 Analog 1 (>98% purity). 
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2.4 Chemical Synthesis of AG10 Analog 2 
 
 
 
The synthesis scheme of AG10 Analog 2 is depicted in Figures 2.4. 
 3  4  AG10 Analog 2
Figur.2.4: Synthesis of AG10 Analog 2. A) Methyl-3-fluoro-5-hydroxybenzoate 4-(3-bromopropyl)-3,5-
dimethyl-1H-pyrazole, K2CO3, DMF, rt, 18-20 hrs; B) NaOH, water, 50 ̊C reflux, 14 hrs. 
 
 
 
methyl 3-[3-(3,5-dimethyl-1H-pyrazol-4-yl)propoxy]-5-fluoro-benzoate (4). To a solution of 
methyl 4-fluoro-3-hydroxybenzoate 3 (101mg, 0.59 mmol, 2.5 equiv) and 4-(3-bromopropyl)-3,5-
di-methyl-1H-pyrazole (87 mg) in DMF (2 mL) was added K2CO3 (101mg, 1.42 mmol, 2.5 
equiv). The reaction mixture was stirred at room temperature (r.t.) for 16 hrs. The mixture was 
diluted with EtOAc (1.5 L), washed with brine (3x0.5 L) and dried with Na2SO4. The solution 
was filtered and concentrated. The residue was purified by flash column chromatography (silica 
gel, 1-10 % EtOAc/hexanes) to afford compound 4 (4.21 g, 82 % yield). 
3-(3-(3,5-Dimethyl-1H-pyrazol-4-yl)propoxy)-4-fluorobenzoic acid (AG10 analog 2). To a 
suspension of 4 (121.25 mg, 0.40 mmol, 1 equiv) in a mixture of MeOH (1.5 mL) and water 
(500µL), NaOH.H2O (33.24 mg, 0.50 mmol, 2 equiv) was added. The reaction mixture was 
25 
 
stirred at 50̊C reflux for 14 hrs. The mixture was extracted with EtOAc (3 x 30 mL) and the 
combined organic extracts were dried over anhydrous sodium sulfate and concentrated in vacuo. 
The crude product was subjected to flash column chromatography (silica gel, 10-50 % 
MeOH/CH2Cl2) to give of AG10 analog 2 (85 mg, 71% yield) as a white solid (>98 % purity by 
HPLC).  
 
 
 
 
Figure.2.5: MS Data showing AG10 Analog 2 (M.WT: 292). 
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Figure 2.6: HPLC trace of AG10 Analog 2 (>98% purity). 
 
 
 
2.5 Fluorescence Polarization (FP) Binding Assay 
Determination of FP Probe Displacement by TTR Ligands.  The affinity of test compounds to 
TTR was determined by their ability to displace FP probe form TTR using our recently developed 
assay [25]. The apparent binding constant was reported as the mean for triplicate experiments and 
the best data fit was determined by R2 value.  
Determination of IC50 using the FP assay; Serial dilutions of AG10 analogs and tafamidis (40 
M to 0.003 M) were added to a solution of FP-probe and TTR in assay buffer (25 L final 
volume). The FP assay was then carried out as described above. 
2.6. Serum TTR selectivity Assay 
The binding affinity and selectivity of the compounds to TTR was determined by their 
ability to compete for covalent probe binding to TTR in human serum as previously reported [26]. 
An aliquot (98 µL) of human serum (Sigma–Aldrich) was mixed with 1 μL of test compounds 
(1.0 mM stock solution in DMSO, final concentration: 10 µM) and 1 μL of probe (0.36 mM stock 
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solution in DMSO: final concentration: 3.6 µM). The fluorescence changes (λex = 328 nm, λem = 
384 nm) were monitored every 15 min using a microplate spectrophotometer reader (Molecular 
Devices SpectraMax M5) for 6 hrs at 25o C. 
2.7 Results 
2.7.1 Binding affinity of AG10 Analogs to TTR 
The binding affinities of the AG10 analogs (Fig. 2) to TTR were evaluated and compared 
to AG10 using our established fluorescence polarization (FP) assay [25]. The FP assay is a 
competitive assay that allows for the measurement of ligand binding to TTR based on their ability 
to displace a fluorescent probe [27] from the TTR T4-binding sites. All test compounds were able 
to bind to TTR (purified from human plasma) at 10 µM. AG10 and new AG10 analogs, were 
assayed in a multi-point dose-response FP assay (concentration range between 40 and 0.00244 
µM). The binding affinity of AG10 to WT-TTR (apparent binding constant, IC50 = 87.39, R2 = 
0.996) were approximately same than that of AG10 analogs (IC50 = 99.6 and 94.5, R2 = 0.998 
and 0.981) (Fig. 2.7).  
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Figure.2.7:  Evaluation of AG10 analogs binding to TTR in buffer by FP. Competition of FP-probe 
from TTR by increasing concentrations (40 to 0.00244 µM) of AG10 (IC50 = 87, R2= 0.996) and AG10 
analogs (IC50 = 99.6 and 94.5, R2 = 0.998 and 0.981). Each point shows the mean ± SD of three replicates. 
 
 
 
Table.2.1: IC50 value of compounds in Fluorescence polarization. 
 
 
 
 
 
 
 
2.7.2 Binding selectivity of AG10 analogs to TTR in human serum 
To stabilize TTR tetramers in FAC and SSA patients, small molecules must selectively 
bind to TTR in the presence of more than 4,000 other serum proteins. We examined the 
selectivity of AG10 analogs for TTR in human serum employing a ligand competition assay using 
a covalent probe (Fig. 2.8)  [23]. The covalent Probe binds selectively to TTR in serum and then 
covalently modifies K15 residue, creating a fluorescent conjugate. Ligands that bind selectively 
Compound Name IC50 Value (nM) Kd value (nM) 
AG10 87.39 18.01 
AG10 Analog 1 99.6 20.53 
AG10 Analog 2 94.5 19.48 
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to TTR in serum decrease the binding of probe to TTR, decreasing the fluorescence [27]. 
However, in addition to selectivity, this assay depends also on the relative affinity of probe and 
the test compound for the TTR binding sites, especially the second binding site (given that 
generally Kd2 > Kd1). Nevertheless, empirically, the results of the probe competition assay at 3 hr 
correlate well with other direct measures of selectivity. The compounds (10 µM) are mixed with 
human serum (TTR concentration ~5 µM) in the presence of probe (3.6 µM). AG10 analogs 
performed better in this assay in serum (42% probe binding for Analog 1 and 41% probe binding  
for Analog 2 after 6 hrs) compared to tafamidis (84% probe binding after 6 hrs) (Fig. 2.8). AG10 
was more selective to TTR (12% probe binding after 6 hrs) than the two new analogs.  
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Figure.2.8: AG10 Analogs binds selectively to TTR in human serum.Fluorescence change caused by 
modification of TTR in human serum by covalent probe monitored for 6 hrs in the presence of probe alone 
(black circles) or probe and TTR ligands (colors). 
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Table.2.2: Percentage of test compound binding to TTR in human serum using covalent probe assay after 3 
hrs. 
 
 
 
 
 
 
 
2.8 Discussion 
  Genetic and pharmacologic data have indicated that kinetic stabilization of tetrameric 
TTR can slow down disease onset and/or progression [28, 29, 21]. Ligands that bind tightly to the 
T4 binding site of TTR reduce tetramer dissociation and subsequent amyloidogenesis. The 
selectivity, affinity and efficacy of TTR stabilizers could be optimized if a compound were able 
to bind to both the inner cavity and the periphery of the T4 binding site. This would be especially 
critical for compounds aimed at stabilization of disease-associated TTR variants. Using AG10 as 
the starting point, we designed two new analogs by changing the position of fluorine atom 
[Figure.2]. We hypothesized that the fluorine atom might have an important role in the binding of 
AG10 analogs to TTR, because the halogen of the AG10 fits in the halogen binding pocket (HBP) 
when AG10 occupies the T4 binding pocket of TTR. Guided by structural information on TTR 
ligands [25], we designed and synthesized two AG10 analogs and tested them for affinity, 
selectivity, and stabilization of TTR. Among all the analogs, AG10 was the most potent 
compound [3]. The new Analogs 1 and 2 displayed higher binding affinity and selectivity to TTR 
than tafamidis. However, AG10 was more selective TTR binder than the new analogs. 
2.9 Conclusion 
The affinity and selectivity of AG10 and newly synthesized AG10 analogs to TTR in 
human serum exceeds that of the FAP drug, tafamidis. The binding selectivity and affinity of 
Test Compound % Binding to TTR 
DMSO 0% 
Tafamidis 16% 
AG10 Analog 1 71.6% 
AG10 Analog 2 72% 
AG10 92% 
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AG10 was much better when compared to AG10 analogs, but still AG10 analogs showed a much 
better affinity and selectivity when compared with tafamidis. The new AG10 analogues will be a 
starting point for further evaluation. Understanding the reason behind the higher potency of AG10 
compared to these analogs would be beneficial for designing stabilizers for other amyloid 
diseases.  
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Chapter3. Optimization of the structure of TTR ligands for half-life extension 
(TLHE) of Therapeutic Peptides 
 
3.1 Introduction 
3.1.1 Peptides. Peptides are small chain of amino acids connected by a peptide bond. Distinguished from 
proteins based on size, peptides have approximately 50 or less amino acids [30]. They are synthesized by 
simple solid phase peptide synthesis where a covalent bond is formed when a carboxyl group of the C-
terminal from one amino acid reacts with amine group of the N-terminal from another amino acid, in 
peptides the shortest peptide is known as a dipeptide and longest one know as a polypeptide. Therapeutic 
peptides are often used in treating a wide range of disorders, such as cancers, diabetes etc [24, 31]. Their 
high selectivity, potency, and safety compared with small molecules, make peptides attractive drug 
candidates.  
Limitations to Use Peptides 
Most peptides have short in vivo half-life (2–30 min) owing to enzymatic degradation by 
proteases and fast renal clearance (molecules <30 kDa are excreted rapidly by glomerular filtration). 
Therefore, extending the in vivo half-life of peptides is clearly desirable for their therapeutic potential to 
be realized without the need for high doses and frequent administration. 
Strategies to Enhance the Half-life of peptides and their Limitations  
There are various methods in the market for increasing the half-life of peptides, the most 
commonly used strategies are as follows [32]: 
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PEGylation 
This method is most commonly used for enhancing the half-life of peptides, where a 
native peptide is modified by conjugation to a polyethylene glycol (PEG) [33]. The peptide which 
was conjugated to the PEG acquires the molecular size of the PEG, escapes excretion by 
glomerular filtration, and escapes the sensitivity of the proteases from degrading which helps in 
increasing blood circulation half-life of the peptides. 
Limitations of PEGylation 
They are a number of drawbacks for PEGylation. For example, PEG is non-
biodegradable and repeated administration of these PEGylated peptides accumulates the PEG in 
kidneys and choroid plexus. The PEG generates anti-PEG antibodies [33] which increases the 
clearance of PEGylated peptides from the body. 
Fusion Protein 
Fusion proteins are created when two or more genes originally coded for different 
proteins are translated into a single or multiple polypeptides, whose function is derived from the 
original protein. In this case, a peptide is genetically fused with human serum albumin (HAS; 67 
kDa) [34] to increase the circulation half-life of the peptides. 
Limitations of Fusion Protein 
The most common problems for this approach are that it has lower affinity towards its 
target receptor, shows long terms immunological toxicities [34] and has stability issues for storing 
and transporting. 
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Lipidation 
Lipidation is a process where a hydrophobic fatty acids are conjugated to the peptide of 
interest [35, 36]. This results in increasing the circulation half-life of the peptides by allowing it 
to bind to human serum albumin. 
Limitations of Lipidation 
The most common limitations for this method are that it shows lower binding towards its 
receptors [35, 36], has some stability issues which make storage and transportation difficult.  
3.2 Conjugation to Transthyretin Ligands 
Transthyretin is a 55 kDa homo-tetramer, liver secrets transthyretin into blood, choroid 
plexus secrets transthyretin in CSF (hTTR concentration in serum is ~ 5 µM) [37] and has in vivo 
half-life of 48 hrs. The primary function of hTTR in human is to transport holo-retinol binding 
protein and secondary function is to transport T4 binding protein in blood. The Apo-retinol 
binding protein which has low binding affinity for hTTR due to the relative small size (21 kDa) 
undergoes fast renal excretion having half-life of 3 hrs [37]. The reversible association between 
the holo-retinol binding protein and hTTR in blood prevents the glomerular filtration of holo-
retinol binding protein which results in enhances the circulation half-life (11 hrs). Based on this 
natural observation, our laboratory previously demonstrated that conjugation of peptides to a 
selective hTTR-binding ligands will help the peptide conjugate to bind reversibly to hTTR and 
helps in increasing the in vivo half-life of therapeutic peptides (Figure.3.1). Due to their eversible 
binding to hTTR, the intrinsic activity of the peptide conjugates are not adversely affected [38].  
Our laboratory developed a potent and selective small molecule hTTR ligand (AG10). At 
10 µM, almost all of AG10 was bound to hTTR in human serum [3, 39]. Our lab also successfully 
developed several AG10-linker modified analogs (TLHEs) which are used for half-life extension 
[39]. 
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3.3 Our Approach 
A major limitation for the above strategies to enhance the half-life of peptides is that the 
steric hindrance of macromolecules often harms the binding affinity of peptides to its extra-
cellular receptors, which undermine the therapeutic potency of peptides. Our approach of using 
TTR ligand for half-life extension (TLHE <500 Da) should not affect the binding affinity of 
peptides to its extra-cellular receptors (Figure 3.1). TLHE are conjugated to peptides through a 
short linker that will give TLHE-peptide conjugate the ability to bind reversibly to T4 binding 
sites of endogenous hTTR [39]. This will increase the in vivo half-life of the peptide by protecting 
against protease and by decreasing glomerular filtration. Importantly, due to its reversible binding 
to hTTR, the binding affinity of the peptide conjugate to its target receptor would not be 
adversely affected. 
 
Figure 3: Current approaches for enhancing the in vivo t1/2 of peptides and our new hTTR based 
approach. (a) Most peptides have short in vivo t1/2 (2–30 minutes) due to enzymatic degradation by 
proteases and fast renal excretion by glomerular filtration. (b) Covalent conjugation of peptides to 
macromolecules such as PEG and HSA enhances the in vivo t1/2 of peptides by sterically protecting the 
peptide from proteases and by increasing the hydrodynamic size of the peptide and therefore decreasing its 
renal excretion. (c) Conjugation of peptides to TTR ligands for half-life extension (TLHEs) (<500 Da), 
through a short linker will form TLHE—peptide conjugates. (d) The TLHE—peptide conjugate can bind 
reversibly to the T4 binding sites of endogenous hTTR (shown as ribbon diagram with transparent surface). 
36 
 
3.4 Development of AG10-Linkers for Conjugating Peptides 
Our lab had made slight change by removing the fluorine atom of AG10 and attaching a 
short linker resulting in TLHE1 (Figure 3.2). TLHE1 maintained good binding affinity and 
selectivity to hTTR [39]. My project involved the synthesis of three new TLHEs (TLHE 2, 3, and 
4; Figure 3.3). We found that TLHE1 has the best binding affinity and selectivity for hTTR. For 
our approach to work in vivo, TLHE1 and its peptide conjugates should be able to selectively 
bind to hTTR in the presence of more than 4,000 other human proteins [39]. The binding 
selectivity of the TLHE-linker peptide conjugate to hTTR in human serum was evaluated using a 
well-established hTTR serum covalent-probe selectivity assay. The lower performance of TLHE1 
compared to AG10 was due to the lower binding affinity of TLHE1 and possibly some binding to 
other serum proteins. Nevertheless, the activity of TLHE1 in this assay was better than that of the 
clinical candidate, tafamidis. TLHE1 was stable in serum for at least 48 hrs and has very low 
cytotoxicity [39]. Therefore, TLHE is a very good candidate for conjugation to peptides. 
Our modeling suggested that lowering the size of linker to TLHE1 to of ̴ 20Å should be 
sufficient to clear the hTTR T4 binding sites and potentially be functionalized with peptides. To 
test our hypothesis we conjugated TLHE1 to three different length linkers. The resulting three 
TLHEs (TLHE2, TLHE3, and TLHE4) were conjugated to the endogenous peptides, 
gonadotropin-releasing hormone (GnRH; 10 amino acid peptide hormone). All Three conjugates 
displayed good binding selectivity for hTTR in human serum. 
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 TLHE 1
 
Figure.3.1: Structure of TLHE1 
 
 
 TLHE 2
 TLHE 4
 TLHE 3
R1= -Glu-His-Trp-Ser-Ty r-Gly -Leu-Arg-Pro-Gly -
 
Figure.3.2: TLHE-Peptide conjugates with different chain linkers. 
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3.5 Methods & Materials 
3.5.1 Materials 
All the peptides, and linkers are synthesized in lab as reported and their reactions were 
carried out under a nitrogen or argon atmosphere and anhydrous conditions, unless noted. The 
solvents used were ACS grade purchased from Fisher Scientific, and reagents were purchased 
from Aldrich and Acros, and used without further purifications. Reactions were monitored using 
thin-layer chromatography (TLC) carried out on 0.2mm POLYGRAM® SIL silica gel plates with 
fluorescent indicator UV254 using UV light as a visualizer. For purification normal phase flash 
column chromatography was carried out using Davisil® silica gel (100-200 mesh, Fisher 
Scientific). High resolution mass spectrometry (HRMS) were used to determine the exact mass of 
synthesized conjugates and peptides by JEOL AccuTOF DART using helium as an ionization gas 
and polyethylene glycol (PEG) as an external calibrating agent. The human serum was obtained 
from Sigma, the probe and AG10 was synthesized as reported in reference [3]. 
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3.6 Chemical synthesis of TLHE1  
The synthesis scheme of TLHE1 is depicted in Figure 3.4 and was synthesized as in reference 
[39]. 
 
 
Figure.3.3: Synthesis of TLHE1. A) 1,3-dibromopropane, K2CO3, DMF, room temperature, 16 hrs; B) 
Acetylacetone, 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU), benzene, room temperature, 3 days; C) 
hydrazine hydrate, ethanol, 90oC, 4 hrs; D) NaOH, THF, water, room temperature, 14 hrs [39].Methyl 3-
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hydroxy-5-pent-4-ynoxy-benzoate. To a solution of methyl 3, 5-dihydroxybenzoate (5) (6.60 g, 
38.93 mmol, 1 equiv) and pent-4-ynyl-4-methylbenzene sulfonate (9.27g, 88.2 mmol, 5 equiv) in 
Acetonitrile (60 mL) was added K2CO3 (2.59 g, 16.6 mmol, 2.2 equiv) and KI (311mg, 22 equiv). 
The reaction mixture was stirred at room temperature (r.t.) for 16 hrs. The mixture was diluted 
with EtOAc (1.5 L), washed with brine (3x0.5 L) and dried with Na2SO4. The solution was 
filtered and concentrated. The residue was purified by flash column chromatography (silica gel, 
1-60 % hexane/DCM) to afford compound (4 g, 82 % yield); to the above dried compound add 
6N HCL (2mL) and THF (2.0mL) and put it under reflux of 50°C for 3.5 hrs then washed with 
250mL water and 500mL EtOAC and collect EtOAC mixture, dry to form compound 6. 
Methyl 5-[5-hydroxy-4-(1-hydroxyethyl)hexoxy]-2-pent-4-ynoxy-benzoate (7). To a solution 
of methyl 5-hydroxy-2-pent-4-ynoxy-benzoate (6) (2.92 g, 3.6 mmol, 1 equiv) and 1,3-
dibromopropane (6.67 mL, 18.2 mmol, 5 equiv) in DMF (40 mL) was added K2CO3 (2.08 g, 4.36 
mmol, 2.4 equiv). The reaction mixture was stirred at room temperature (r.t.) for 16 hrs. The 
mixture was diluted with EtOAc (1.5 L), washed with brine (3x0.5 L) and dried with Na2SO4. A 
solution of (7) (840 mg, 2.36 mmol, 1 equiv) in benzene (2 mL) was added dropwise to  a 
solution of acetyl acetone (1.79 mL, 4.73 mmol, 2 equiv) and DBU (2.638 mL, 4.73 mmol, 2 
equiv) in benzene (28 mL). The reaction mixture was stirred at r.t. for 3 days. The mixture was 
filtered and concentrated. The residue was purified by flash column chromatography (silica gel, 
1-10 % EtOAc/hexanes) to afford compound (8) which was used in the next step directly. 
Hydrazine hydrate (456 mL, 6.73 mmol, 2.5 equiv) was added to a solution (8) in ethanol (15 
mL) and the reaction was heated under reflux for 4 hrs. The reaction was concentrated and 
purified by flash column chromatography (silica gel, 1-20 % MeOH/CH2Cl2) to afford compound 
(9) (288 mg, 35% yield) in two steps; 
3-[3-(3,5-dimethyl-1H-pyrazol-4-yl)propoxy]-5-pent-4-ynoxy-benzoic acid (TLHE1). To a 
suspension of (9) (100 mg, 0.0946 mmol, 1 equiv) in a mixture of  NaOH.H2O (11.89 mg, 0.189 
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 mmol, 2 equiv) was added to the MeOH (4mL). The reaction mixture was stirred under reflx of 
50°C for 12 h after which it was cooled to room temperature. The mixture was fractionated with 
EtOAc and MeOH at different concentrations and finally run a thin layer chromatography after 
conforming the fraction with compound dry the fraction. The crude product was subjected to 
flash column chromatography (silica gel, 10-50% MeOH/CH2Cl2) to give of TLHE1 (30 mg, 
32% yield) as a white solid (95% purity by HPLC) 
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3.7 Chemical synthesis of GnRH analog 1 (TLHE2-GnRH) 
 
Figure.3.4: Synthesis of TLHE2-GnRH. Reagents and conditions: a) Rink amide resin, DIPEA, DCM, 16 
hrs; b) Fmoc SPPS (all L-amino acids); c) Linker, HATU, HOBt, DIPEA, DMF, 24 hrs; d) TLHE1, Cu, 
sodium ascorbate, DMF/piperidine (4:1), 16 hrs; e) TFA, phenol, H2O, and TIS (88:5:5:2 ratio) 3 hrs. 
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Synthesis of GnRH 
 The GnRH Peptide was synthesized using standard solid phase synthesis utilizing 
Fmoc/tBu protocols. All amino acids used for synthesis are L-Amino acids. The synthesis was 
carried out on a rink amide MBHA resin (NovobioChem #855003, 0.79 mmol/g). For the resin 
loading step, the resin (250mg, 0.1975 mmol) was reacted with Fmoc-Gly-OH () in DMF (3mL) 
and DIC (0.137 mL, 0.875 mmol). The reaction mixture was shaken for 5hrs, the peptides were 
built by coupling Fmoc protected (L) amino acid monomers to the first amino-acid attached to the 
rink amide resin using DIC, HOBT, in DMF and shaken for 2hrs. Once the GnRH deca-peptide 
synthesis was completed, it was dried and used for conjugating the linker. 
Synthesis of GnRH-Linker   
 The azide PEG-linker 3[2-[2-(2- azidoethoxy)ethoxy]ethoxy] proponoic acid was used 
directly after synthesis from 3[2-[2-(2-Hydroxyethoxy)ethoxy]ethoxy]propanoic acid tert-butyl 
ester taken with Triethylene glycol (104.45 g) with THF (40mL). Then NaOH (5.581 g) mixed 
with deionized water (30 mL) are added to the round bottom flask at 0°C, the reaction mixture 
was stirred for 15 min. PTScl dissolved in THF (100mL) was added dropwise and stirred for 2hrs 
at 0°C. The reaction mixture was washed with water/EtOAc in a separation flask. The EtOAc was 
collected concentrated, flash column was done using MeOH/DCM (50:50) which formed purified 
(2-[2-(2-hydroxysulphonylethoxy) ethoxy] ethanol). The product was further synthesized by 
mixing in DMF (30mL) under nitrogen. Sodium Azide is added and refluxed for half-hour. Then 
200mL of water was added to the reaction and (50mL) of EtOAc was added multiple time to 
extract compound it was concentrated and purified using a flash column to separate pure 
compound. Ethanol, 2-[2-(2-azidoethoxy)ethoxy] (200mg) was further dissolved with acetone 
(12mL) and kept at 0°C, Chromium oxide (521.1mg) in 1.5m of sulfuric acid (6mL) was slowly 
added at 0°C, then the reaction is slowly changed to room temperature for overnight. Finally 
isopropanol was added to quench the reaction. The final compound (2-[2-(2- azidoethoxy) 
ethoxy] acetic acid) is dried and stored. 
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 The GnRH peptide-linker was synthesized in a similar way to what described above for 
GnRH synthesis. The only difference is that we used glutamic acid instead of pyro-glutamic acid 
the N-terminus. The azide PEG linker (37.5 mg, 0.198 mmol) is activated in HATU (150.6 mg, 
0.396 mmol), HOBT (53.58 mg, 0.396 mmol), DIPEA (51.2 mg, 0.396 mmol) and DMF (3mL). 
All the reagents are added to the GnRH peptide before the product was cleaved from the resin, the 
reaction mixture was shaken for 20 hrs.  
Synthesis of TLHE2-GnRH  
 The click reaction was carried out by the resin bound GnRH-linker (0.132 mmole), 3-[3-
(3, 5-dimethyl-1H-pyrazol-4-yl)propoxy]-5-pent-4-ynoxy-benzoic acid (34 mg, 0.132mmol), 
copper iodide (75mg, 0.132mmol), Sodium ascorbate (78.4 mg, 0.132mmol), DMF/piperidine 
(4:1) 3mL, the mixture was transferred into the reaction flask under nitrogen gas and reaction was 
left for 16 hrs in room temperature. The product was then cleaved from the resin including the 
deprotonation of groups present in the side chains groups was performed by treating with 
cleavage cocktail which contains TFA, phenol, water, and TIS (88:5:5:2) ratio, shaken with this 
cocktail for 1 to 1 ½hr. After cleavage the resulting product was collected in cold ether and 
washed multiple times with ether and finally centrifuged to separate the GnRH peptide-linker-
conjugate in the form of precipitate, the precipitate was dried and purified using preparative 
HPLC using (50:50) of buffer for injecting the peptide conjugate using buffer solvent A and B 
(buffer A: water, methanol, TFA at ratio 95:5:0.1) and (buffer B: methanol, water, TFA at ratio 
95:5:0.1) using C18 column. 
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Figure 3.5: MS data showing TLHE2-GnRH (M.Wt: 1787.5).  
 
 
Figure 3.6: HPLC trace of TLHE2-GnRH (>98 % purity). 
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3.8 Chemical synthesis of GnRH analog 2 (TLHE3-GnRH) 
 
Figure.3.7: Synthesis of TLHE3-GnRH. Reagents and conditions: a) Rink amide resin, DIPEA, DCM, 16 
h; b) Fmoc SPPS (all L-amino acids); c) Linker, HATU, HOBt, DIPEA, DMF, 24 h; d) TLHE1, CuI, 
sodium ascorbate, DMF/piperidine (4:1), 16 h; e) TFA, phenol, H2O, and TIS (88:5:5:2 ratio) 3h. 
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Chemical Synthesis of GnRH 
 The synthesis of the peptide is same as previously explained in (3.7) 
Synthesis of GnRH-Linker  
 The azide PEG-linker (2-[2-(2- azidoethoxy) ethoxy] acetic acid) was used directly after 
synthesis from (2-[2-(2-hydroxyethoxy) ethoxy] ethanol) taken with T-glycol (104.45 g) with 
THF (40mL). Then NaOH (5.581 g) mixed with deionized water (30 mL) was slowly added to a 
round bottom flask at 0°C, the reaction mixture was stirred for 15 minutes. PTScl dissolved in 
THF (100mL) was added dropwise and stirred for 2hrs at 0°C. The reaction mixture was washed 
with water/EtOAc in a separation flask, The EtOAc was collected concentrated, and flash column 
was done using MeOH/DCM (50:50) and which formed purified (2-[2-(2-
hydroxysulphonylethoxy) ethoxy] ethanol). The product was further synthesized by mixing in 
DMF (30mL) under nitrogen Sodium azide was added and refluxed for half-hour, then 200mL of 
water was added to the reaction and (50mL) of EtOAc was added multiple time to extract 
compound it was concentrated and purified using a flash column to separate pure compound. 
Ethanol, 2-[2-(2-azidoethoxy)ethoxy] (200mg) was then dissolved with acetone (12mL) and kept 
at 0°C, chromium oxide (521.1mg) in 1.5M sulfuric acid (6mL) was slowly added at 0°C. The 
reaction then gradually changed to room temperature for overnight. Finally isopropanol was 
added to quench the reaction. The final compound (2-[2-(2- azidoethoxy) ethoxy] acetic acid) was 
dried and stored. 
 The GnRH peptide- Linker was synthesized in a similar way to what described above for 
the GnRH synthesis. The only difference is that we used glutamic acid instead of pyro-glutamic 
acid at N-terminus. The azide PEG linker (37.5 mg, 0.198 mmol) is activated in HATU (150.6 
mg, 0.396 mmol), HOBT (53.58 mg, 0.396 mmol), DIPEA (51.2 mg, 0.396 mmol) and DMF 
(3mL). All the reagents are added to the GnRH peptide before the product was cleaved from the 
resin, the reaction mixture was shaken for 20 hrs.  
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Synthesis of TLHE3-GnRH 
 The click reaction was carried out by the resin bound GnRH-linker (0.132 mmole), 3-[3-
(3, 5-dimethyl-1H-pyrazol-4-yl)propoxy]-5-pent-4-ynoxy-benzoic acid (34 mg, 0.132mmol), 
copper iodide (75mg, 0.132mmol), Sodium ascorbate (78.4mg, 0.132mmol), DMF/piperidine 
(4:1) 3mL, the mixture was transferred into the reaction flask under nitrogen gas and reaction was 
left for 16 hrs in room temperature. The product was then cleaved from the resin including the 
deprotonation of groups present in the side chains groups was performed by treating with 
cleavage cocktail which contains TFA, phenol, water, and TIS (88:5:5:2) ratio, shaken with this 
cocktail for 1 to 1 ½hr. After cleavage the resulting product was collected in cold ether and 
washed multiple times with ether and finally centrifuged to separate the GnRH peptide-linker-
conjugate in the form of precipitate, the precipitate was dried and purified using preparative 
HPLC using (50:50) of buffer for injecting the peptide conjugate using buffer solvent A and B 
(buffer A: water, methanol, TFA at ratio 95:5:0.1) and (buffer B: methanol, water, TFA at ratio 
95:5:0.1) using C18 column. 
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Figure 3.8: MS data showing TLHE3-GnRH (M.Wt: 1728).  
 
 
Figure 3.9: HPLC trace of TLHE3-GnRH (>99.20 % purity). 
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3.9 Chemical synthesis of TLHE4-GnRH 
 
Figure.3.10: Synthesis of TLHE4-GnRH. Reagents and conditions: a) Rink amide resin, DIPEA, DCM, 
16 h; b) Fmoc SPPS (all L-amino acids); c) Linker, HATU, HOBt, DIPEA, DMF, 24 h; d) TLHE1, CuI, 
sodium ascorbate, DMF/piperidine (4:1), 16 h; e) TFA, phenol, H2O, and TIS (88:5:5:2 ratio) 3 hrs. 
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Synthesis of GnRH 
The synthesis of the peptide is same as previously explained in (3.7). Synthesis of GnRH-
Linker 
    The azide PEG-linker (5-Azido pentaonic acid) was ordered from Sigma Aldrich (CAS 
Number 79583-98-5), and The GnRH peptide- Linker is synthesized in a similar way to what 
described above for GnRH synthesis, the only difference was here we are using glutamic acid 
instead of pyro-glutamic acid  at N-terminus. The azide PEG linker (27.91mg, 0.065 mmol) is 
activated in HATU (74.14mg, 0.065 mmol), HOBT (29.86 mg, 0.065 mmol), DIPEA (16.79 mg, 
0.065 mmol) and DMF (3mL). All the reagents are added to the GnRH peptide before the product 
was cleaved from the resin, the reaction mixture was shaken for 20 hrs.  
Synthesis of TLHE4-GnRH  
 The click reaction was carried out by the resin bound GnRH-linker (0.132 mmole), 3-[3-
(3, 5-dimethyl-1H-pyrazol-4-yl)propoxy]-5-pent-4-ynoxy-benzoic acid (34 mg, 0.132mmol), 
copper iodide (75mg, 0.132mmol), Sodium ascorbate (78.4mg, 0.132mmol), DMF/piperidine 
(4:1) 3mL, the mixture was transferred into the reaction flask under nitrogen gas and reaction was 
left for 16 hrs in room temperature. The product was then cleaved from the resin including the 
deprotonation of groups present in the side chains groups was performed by treating with 
cleavage cocktail which contains TFA, phenol, water, and TIS (88:5:5:2) ratio, shaken with this 
cocktail for 1 to 1 ½hr. After cleavage the resulting product was collected in cold ether and 
washed multiple times with ether and finally centrifuged to separate the GnRH peptide-linker-
conjugate in the form of precipitate, the precipitate was dried and purified using preparative 
HPLC using (50:50) of buffer for injecting the peptide conjugate using buffer solvent A and B 
(buffer A: water, methanol, TFA at ratio 95:5:0.1) and (buffer B: methanol, water, TFA at ratio 
95:5:0.1) using C18 column. 
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Figure 3.11: MS data showing TLHE4-GnRH (M.Wt: 1682.4).  
 
 
 
Figure 3.12: HPLC trace of TLHE4-GnRH (>97 % purity). 
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3.10 Results 
3.11 TLHE-GnRH Conjugates Bind Selectively to WT-TTR in Human Serum 
The selectivity of TLHE-GnRH conjugates to hTTR in human serum was evaluated using 
a well-established hTTR serum covalent-probe selectively assay [3, 39, 23] as shown in 
(Fig.3.14) The lower performance of TLHE-Peptide analogs TLHE2-GnRH, TLHE3-GnRH, 
and TLHE4-GnRH (47%, 46%, and 36% binding to hTTR in serum) compared to AG10 (Kd = 
13.8 nM; 87% binding to hTTR in serum) was due to the lower binding affinity of conjugates to 
hTTR and possibly some binding to other serum proteins. However, the binding affinity and 
selectivity of TLHE-GnRH conjugated in this assay were better than that of the clinical candidate, 
tafamidis (16% binding to hTTR in serum). 
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Figure.3.13: Fluorescence change caused by covalent probe (hTTR concentration, ~5 μM) by covalent 
probe monitored for 6 h in the presence of covalent probe alone (black circles) or covalent probe and 
GnRH attached hTTR ligands (colors; 10 μM). The lower the binding and fluorescence of covalent probe, 
the higher binding selectivity of ligand to hTTR. Each bar shows the mean ± SD of three replicates. 
Table.3.1: Showing the percentage of TLHE-GnRH binding to hTTR in human serum using covalent 
probe Assay after (3 hrs). 
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Compound Name % Binding to TTR 
DMSO 11% 
Tafamidis 30% 
TLHE2-GnRH 61% 
TLHE4-GnRH 67% 
TLHE3-GnRH  69% 
AG10 94% 
 
 
 
3.12 hTTR Protected TLHE-GnRH Conjugates against Serum Protease 
We tested the ability of hTTR to protect TLHE-GnRH conjugates against proteolytic 
hydrolysis in human serum. The stability of the conjugates was evaluated in human serum (hTTR 
conc. ~5 µM). It was determined that the GnRH peptide had the lowest stability in serum (no 
amount detected after 8 hrs). Attaching three different linkers to GnRH (GnRH-linker) enhanced 
their stability. However they still are considered small molecules which are rapidly excreted by 
the kidneys. Therefore, we conjugated linker-GnRH to the TLHEs which has a good binding 
affinity with TTR, to see whether it protects the peptide from protease and glomerular filtration 
by increasing the molecule’s size. After performing the serum protease stability assay we found 
that the stability of the conjugates was enhanced and GnRH-conjugates were protected against 
serum protease degradation in comparison to GnRH (Fig.3.15 and Table- 3.2). 
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Figure.3.14: hTTR protected TLHE4-GnRH 62%, TLHE2-GnRH 38%, and TLHE3-GnRH 36%, 
against proteolytic hydrolysis in human serum. Test compounds (5 μM) were added to serum and to serum. 
The amounts of compounds remaining in serum were quantitated at indicated time points. Each point 
shows the mean ± SD of three replicate. 
 
 
Table 3.2: Showing the percentage of the THLE-GnRH conjugates remaining in human serum 
after 48 hrs of incubation. 
 
 
 
 
 
Compound Name % Remaining in serum after 48 
hrs 
GnRH 0% 
TLHE2-GnRH 38% 
TLHE3-GnRH 36% 
TLHE4-GnRH 62% 
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3.13 Binding affinity of TLHE-GnRH conjugates to TTR 
 The binding affinity of TLHE-GnRH conjugates to TTR at physiological pH was 
evaluated using our established fluorescence polarization (FP) assay [25]. The FP assay is a 
competitive assay that allows measurement of ligand binding to TTR based on their ability to 
displace a fluorescent probe [27] from the TTR T4-binding sites. All test compounds were able to 
bind to TTR (purified from human plasma) at 10 µM. The TLHE-GnRH conjugates and AG10 
were then assayed in a multi-point dose-response FP assay (concentration range between 40 and 
0.02 µM). The binding affinity of AG10 to TTR (apparent binding constant, IC50 = 85.36 nM, R2 
= 0.991) was better than the GnRH- analogs and TLHE ligands. The binding affinity of TLHE1 
and to TTR (TLHE1; IC50 = 204.3 nM, R2 = 0.9905). The binding affinity of GnRH- analogs to 
WT-TTR were as follows: TLHE2-GnRH (IC50 = 1047.64 nM, R2=0.99); TLHE3-GnRH (IC50 = 
1370.16 nM, R2=0.98); TLHE4-GnRH (IC50 = 1505 nM, R2=0.9815) (Figure.3.16 and table 
3.16.1). 
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Figure.3.15: Evaluation of ligand binding to TTR in buffer by FP. Competition of FP-probe from TTR 
by increasing concentrations (40 and 0.02 µM) of TLHE-GnRH conjugates: TLHE3-GnRH (IC50 = 1047.64 
nM, R2=0.99); TLHE2-GnRH (IC50 = 1370.16 nM, R2=0.98); TLHE4-GnRH (IC50 = 1505 nM, R2=0.9815). 
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Each point shows the mean ± SD of three replicates. Table.3.3: IC50 value for binding affinity of TLHE-
GnRH conjugates to TTR using Fluorescence polarization 
Compound Name IC50 (nM) Value Kd (nM)Value 
AG10 85.36 17.6 
TLHE1 90 18.55 
TLHE2-GnRH 1370.64 285.45 
TLHE3-GnRH 1047.16 234.2 
TLHE4-GnRH 1505.28 310.30 
 
. 
 
3.14 Discussion 
There are various attractive technologies like conjugation to PEG and albumins for large 
peptides and proteins, which enhance the half-life of peptides. However; these strategies have 
some limitations, such as non-biodegradability, immunogenicity and low binding affinity with the 
target receptors because of the steric hindrance. Therefore, the TLHE1 system has the potential to 
optimize half-life extension of peptides without affecting the binding with their receptors. In 
addition, our approach offers a number of additional advantages over other strategies. Our 
technology involves a simple chemical conjugation of the peptide to TLHE1, and the products are 
homogenous, easily characterized and purified in harsh conditions like HPLC. 
GnRH agonist is a ten amino acid peptide used to treat prostate and breast cancers, as 
well as fertility disorders yet it has a small half-life. Our THLE technology increased the half-life 
of GnRH-analogs by improving their binding affinity and selectivity to hTTR.  
3.15 Conclusion 
Conjugation of peptides and proteins to PEG and albumin are considered as an attractive 
technology, But the TLHE system has additional advantages for enhancing the half-life of 
peptides.  Besides maintaining the potency, our technology provides a number of advantages over 
traditional genetic fusion, PEGylation and human serum albumin conjugations. Our approach 
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involves in a simple chemical conjugation of peptides, linkers and TLHEs, and the products are 
homogenous and can be easily purified and characterized using harsh conditions such as HPLC. 
The nature of synthesis offers flexibility of attachment sites and incorporates the unnatural amino 
acids or non-peptidic functionality into the peptide. Unlike HSA peptide conjugation, where the 
three-dimensional structure of the fusion partner need to be maintained, but conjugation to 
TLHEs results in stable product that do not need refrigeration, which decreases the cost of 
production, transportation and storage. Because of the small size we anticipate our conjugates 
penetrate solid tumors efficiently. Due to non-peptidic nature and small size, it is unlikely that 
TLHEs will cause any immunogenic response. 
From the preliminary screening of the synthesized TLHE-GnRH conjugates, we can 
conclude that lowering the linker length provide better selectivity and protection against serum 
protease cleavage.  
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